Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

Consumption of B-GOS prebiotic has positive effect on gut microbiota, immune systems of elderly people

Clasado Biosciences Limited, the producers and suppliers of the second generation prebiotic Bimuno, a unique trans-galactooligosaccharide, and the Department of Food and Nutritional Sciences, The University of Reading, UK, today announce the results of human research demonstrating the positive effects of an advanced prebiotic on the immune system of the elderly.

29 Jul 2015

Inflammation plays role in onset of delirium in older adults

Delirium is an acute state of confusion that often affects older adults following surgery or serious illness. Now a study led by researchers at Beth Israel Deaconess Medical Center confirms that inflammation - an immune response that develops when the body attempts to protect itself from harmful stimuli -- plays a role in the onset of delirium.

28 Jul 2015

Gene responsible for cancer growth plays unexpected role in prostate cancer

A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.

22 Jul 2015

New study suggests novel ways to treat serous retinal detachment

Wet age-related macular degeneration (AMD) is the leading cause of severe vision loss in older individuals. AMD and other serious chronic eye problems that affect younger individuals result when fluid accumulates abnormally under or within the retina. A new study published in The American Journal of Pathology shows for the first time that the release of substances from mast cells may be a causal factor in this type of eye pathology, and inhibitors of this release may offer new ways to treat serous retinal detachment.

22 Jul 2015

Sulfur dioxide air pollutant can cause adverse effects in asthmatics

Emissions of the air pollutant sulfur dioxide have been dramatically decreased during the past 30 years but for some people even a little inhaled sulfur dioxide may still be too much.

17 Jul 2015

New findings point toward potential blood test to detect schizophrenia

High blood levels of a growth factor known to enable new blood vessel development and brain cell protection correlate with a smaller size of brain areas key to complex thought, emotion and behavior in patients with schizophrenia, researchers report in the journal Molecular Psychiatry.

16 Jul 2015

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared psoriasis or minimal psoriasis at week 16, the study's primary endpoint.

9 Jul 2015

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001.

1 Jul 2015

ALS ACT initiative to speed discovery of new ALS treatments

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative.

1 Jul 2015

Nuclea and Aelan partner to develop, commercialize novel biomarker tests using STEM cells as models

Nuclea Biotechnologies Inc. announced today that it is partnering with Aelan Cell Technologies Inc. (San Francisco, California) for the development, validation and commercialization of novel biomarker tests and companion diagnostics using human STEM cells as models.

1 Jul 2015

dlDNA marks progression of HBV-related liver disease

The level of serum duplex-linear DNA increases markedly with liver disease progression and development of hepatocellular carcinoma in patients with chronic hepatitis B virus (HBV) infection, suggests research published in Gut.

30 Jun 2015

Weight loss, combined with vitamin D supplements, reduces chronic inflammation

For the first time, researchers at Fred Hutchinson Cancer Research Center have found that weight loss, in combination with vitamin D supplementation, has a greater effect on reducing chronic inflammation than weight loss alone. Chronic inflammation is known to contribute to the development and progression of several diseases, including some cancers.

26 Jun 2015

Weight loss along with vitamin D supplementation reduces chronic inflammation

25 Jun 2015

Cytokine levels may help distinguish patients with suicidality

One American dies from suicide every 12.8 minutes, making suicide the tenth leading cause of death in the United States according to the American Foundation for Suicide Prevention.

25 Jun 2015

Researchers discover that extreme exercise can lead to blood poisoning

Researchers have discovered that extreme exercise can cause intestinal bacteria to leak into the bloodstream, leading to blood poisoning.

17 Jun 2015

Experts review strategies that may help improve adoptive cell immunotherapy for treating cancer

In a special issue of Immunotherapy, leading experts provide in-depth review of innovative strategies that may further the success of adoptive cell immunotherapy as a cancer treatment. Adoptive cell immunotherapy (ACT) has proven successful in clinical trials against certain types of melanoma and leukemia. The journal reviews new strategies to address the challenges of extending these effects to a wider range of tumor types.

17 Jun 2015

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC).

16 Jun 2015

Modifying small white blood cells may help treat immune disorders

Modifying the small white blood cells that protect against disease might help treat immune disorders, according to a study published in Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association.

16 Jun 2015

Researchers uncover new mechanism that innate immune system uses to curb viral infections

An innovative mechanism that the innate immune system uses to control viral infections has been uncovered by researchers at the University Medical Centers in Mainz and Freiburg. Central to this is the discovery that two different but related elements of the immune system can act together in concert to fight, for example, rotavirus infections.

16 Jun 2015

Ixekizumab drug shows quick and extensive improvements in patients with psoriasis

A University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement.

11 Jun 2015

Interleukin 6 News and Research

Further Reading

Consumption of B-GOS prebiotic has positive effect on gut microbiota, immune systems of elderly people

Inflammation plays role in onset of delirium in older adults

Gene responsible for cancer growth plays unexpected role in prostate cancer

New study suggests novel ways to treat serous retinal detachment

Sulfur dioxide air pollutant can cause adverse effects in asthmatics

New findings point toward potential blood test to detect schizophrenia

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

ALS ACT initiative to speed discovery of new ALS treatments

Nuclea and Aelan partner to develop, commercialize novel biomarker tests using STEM cells as models

dlDNA marks progression of HBV-related liver disease

Weight loss, combined with vitamin D supplements, reduces chronic inflammation

Weight loss along with vitamin D supplementation reduces chronic inflammation

Cytokine levels may help distinguish patients with suicidality

Researchers discover that extreme exercise can lead to blood poisoning

Experts review strategies that may help improve adoptive cell immunotherapy for treating cancer

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

Modifying small white blood cells may help treat immune disorders

Researchers uncover new mechanism that innate immune system uses to curb viral infections

Ixekizumab drug shows quick and extensive improvements in patients with psoriasis

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News